The impact of different IPV-OPV sequential immunization programs on hepatitis A and hepatitis B vaccine efficacy

References

• Bandyopadhyay AS, Garon J, Seib K, Orenstein WA. Polio vaccination: past, present and future. Future Microbiol. 2015;10:791–6. PMID: 25824845. doi:10.2217/fmb.15.19.
   PubMed Web of Science ®Google Scholar
• Global Polio Eradication Initiative. Two out of three wild poliovirus strains eradicated. Global Polio Eradication Initiative, World Health Organization, Geneva, Switzerland. 2019
   Google Scholar
• Ghendon Y, Robertson SE. Interrupting the transmission of wild polioviruses with vaccines: immunological considerations. Bull World Health Organ. 1994;72:973–83. PMID: 7867144.
   PubMed Web of Science ®Google Scholar
• Patel M, Zipursky S, Orenstein W, Garon J, Zaffran M. Polio endgame: the global introduction of inactivated polio vaccine. Expert Rev Vaccines. 2015;14:749–62. PMID: 25597843. doi:10.1586/14760584.2015.1001750.
   PubMed Web of Science ®Google Scholar
• Hampton LM, Farrell M, Ramirez-Gonzalez A, Menning L, Shendale S, Lewis I, Rubin J, Garon J, Harris J, Hyde T, et al. Cessation of trivalent oral poliovirus vaccine and introduction of inactivated poliovirus vaccine - worldwide, 2016. MMWR Morb Mortal Wkly Rep. 2016;65:934–38. PMID: 27606675. doi:10.15585/mmwr.mm6535a3.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Meeting of the strategic advisory group of experts on immunization, November 2012 – conclusions and recommendations. Wkly Epidemiol Rec. 2013; 88:1–16. PMID: 23311010.
   PubMedGoogle Scholar
• World Health Organization. Guidelines for the safe production and quality control of inactivated poliomyelitis vaccine manufactured from wild polioviruses. Addendum to the Recommendations for the production and quality control of poliomyelitis vaccine (inactivated) WHO Technical Report Series, 2004, Annex. 2003.
   Google Scholar
• China; NHaFPCotPsRo. Immunization schedules and instructions for vaccines of the national immunization program(2016 Version). Chin J Viral Dis. 2017;7(2):81–86. PMID: 27279955. doi:10.11604/pamj.2016.23.128.8756.
   Google Scholar
• Luo J, Wang X, Ma F, Kang G, Ding Z, Ye C, Pan Y, Zhao Y, Hong S, Chen J, et al. Long-term immunogenicity and immune persistence of live attenuated and inactivated hepatitis a vaccines: a report on additional observations from a phase IV study. Clin Microbiol Infect. 2019;25:1422–27. PMID: 30496870. doi:10.1016/j.cmi.2018.11.005.
   PubMed Web of Science ®Google Scholar
• Fangcheng Z, Xuanyi W, Mingding C, Liming J, Jie W, Qi J, Yuanping G, Wen Q, Yajuan X, Jiangsen M, et al. Era of vaccination heralds a decline in incidence of hepatitis A in high-risk groups in China. Hepat Mon. 2012;12:100–05. PMID: 22509186. doi:10.5812/hepatmon.838.
   PubMed Web of Science ®Google Scholar
• Zhang X, An J, Tu A, Liang X, Cui F, Zheng H, Tang Y, Liu J, Wang X, Zhang N, et al. Comparison of immune persistence among inactivated and live attenuated hepatitis a vaccines 2 years after a single dose. Hum Vaccin Immunother. 2016;12:2322–26. PMID: 27494260. doi:10.1080/21645515.2015.1134069.
   PubMed Web of Science ®Google Scholar
• Bhave S, Sapru A, Bavdekar A, Kapatkar V, Mane A. Long-term immunogenicity of single dose of live attenuated hepatitis A vaccine in Indian children. Indian Pediatr. 2015;52:687–90. PMID: 26388627. doi:10.1007/s13312-015-0697-8.
   PubMed Web of Science ®Google Scholar
• Lemon SM. Immunologic approaches to assessing the response to inactivated hepatitis A vaccine. J Hepatol. 1993;18(Suppl 2):S15–S19. PMID: 8182266. doi:10.1016/s0168-8278(05)80372-1.
   PubMedGoogle Scholar
• Song YJ, Lim J, Park WS, Sohn H, Lee MS, Shin DH, Kim CB, Kim H, Oh GJ, Ki M. Seropositivity among Korean Young Adults Approximately 2 years after a single-dose vaccination against Hepatitis A virus. PLoS One. 2015;10:e0142297. PMID: 26540392. doi:10.1371/journal.pone.0142297.
   PubMed Web of Science ®Google Scholar
• Li J, Zhang ZJZ, Pan JB, Zhang HR, Li RQ, Li MZ, Lu L, Huang F, Wu J. Surveillance of immunization effectiveness and titer of type I and type III polio vaccine in Beijing before and after the adjustment of immunization strategy in 2012-2018. Zhonghua Yu Fang Yi Xue Za Zhi. 2020;54:779–83. doi:10.3760/cma.j.cn112150-20190621-00499.
   PubMedGoogle Scholar
• Ciapponi A, Bardach A, Rey Ares L, Glujovsky D, Cafferata ML, Cesaroni S, Bhatti A. Sequential inactivated (IPV) and live oral (OPV) poliovirus vaccines for preventing poliomyelitis. Cochrane Database Syst Rev. 2019;12:Cd011260. PMID: 31801180. doi:10.1002/14651858.CD011260.pub2.
   PubMedGoogle Scholar
• O’Ryan M, Bandyopadhyay AS, Villena R, Espinoza M, Novoa J, Weldon WC, Oberste MS, Self S, Borate BR, Asturias EJ, et al. Inactivated poliovirus vaccine given alone or in a sequential schedule with bivalent oral poliovirus vaccine in Chilean infants: a randomised, controlled, open-label, phase 4, non-inferiority study. Lancet Infect Dis. 2015;15:1273–82. PMID: 26318714. doi:10.1016/S1473-3099(15)00219-4.
   PubMed Web of Science ®Google Scholar
• Asturias EJ, Bandyopadhyay AS, Self S, Rivera L, Saez-Llorens X, Lopez E, Melar M, Gaensbauer JT, Weldon WC, Oberste MS, et al. Humoral and intestinal immunity induced by new schedules of bivalent oral poliovirus vaccine and one or two doses of inactivated poliovirus vaccine in Latin American infants: an open-label randomised controlled trial. Lancet. 2016;388:158–69. PMID: 27212429. doi:10.1016/S0140-6736(16)00703-0.
   PubMed Web of Science ®Google Scholar
• Tang G, Yin W, Cao Y, Tan L, Wu S, Cao Y, Fu X, Yan J, Jiang X. Immunogenicity of sequential inactivated and oral poliovirus vaccines (OPV) versus inactivated poliovirus vaccine (IPV) alone in healthy infants: a systematic review and meta-analysis. Hum Vaccin Immunother. 2018;14:2636–43. PMID: 29985751. doi:10.1080/21645515.2018.1489188.
   PubMed Web of Science ®Google Scholar
• Kanra G, Yalçin SS, Ceyhan M, Yurdakök K. Clinical trial to evaluate immunogenicity and safety of inactivated hepatitis A vaccination starting at 2-month-old children. Turk J Pediatr. 2000;42:105–08. PMID: 10936974.
   PubMed Web of Science ®Google Scholar
• Linder N, Karetnyi Y, Gidony Y, Ohel G, Levin E, Kuint J, Davidovich N, Gidony I, Mendelson E, Barzilai A. Placental transfer of hepatitis A antibodies in full term and preterm infants. Pediatr Infect Dis J. 1997;16:245–47. PMID: 9041609. doi:10.1097/00006454-199702000-00015.
   PubMed Web of Science ®Google Scholar
• Linder N, Karetnyi Y, Gidony Y, Dagan R, Ohel G, Levin E, Mendelson E, Brazilai A. Decline of hepatitis A antibodies during the first 7 months of life in full-term and preterm infants. Infection. 1999;27:128–31. PMID: 10219645. doi:10.1007/BF02560513.
   PubMed Web of Science ®Google Scholar
• López EL, Contrini MM, Xifró MC, Cattaneo MA, Zambrano B, Dumas R, Rouyrre N, Weber F. Hepatitis A vaccination of Argentinean infants: comparison of two vaccination schedules. Vaccine. 2007;25:102–08. PMID: 16914234. doi:10.1016/j.vaccine.2006.07.014.
   PubMed Web of Science ®Google Scholar
• Liu XE, Wushouer F, Gou A, Kuerban M, Li X, Sun Y, Zhang J, Liu Y, J LI, Zhuang H. Comparison of immunogenicity between inactivated and live attenuated hepatitis A vaccines: a single-blind, randomized, parallel-group clinical trial among children in Xinjiang Uighur Autonomous Region, China. Hum Vaccin Immunother. 2013;9:1460–65. PMID: 23571173. doi:10.4161/hv.24366.
   PubMed Web of Science ®Google Scholar
• Wang Z, Zhang S, Luo C, Wu Q, Liu Q, Zhou YH, Hu Y. Transplacentally acquired maternal antibody against hepatitis B surface antigen in infants and its influence on the response to hepatitis B vaccine. PLoS One. 2011;6:e25130. PMID: 21966434. doi:10.1371/journal.pone.0025130.
   PubMed Web of Science ®Google Scholar
• Roznovsky L, Orsagova I, Kloudova A, Tvrdik J, Kabieszova L, Lochman I, Mrazek J, Hozakova L, Zjevikova A, Pliskova L. Long-term protection against hepatitis B after newborn vaccination: 20-year follow-up. Infection. 2010;38:395–400. PMID: 20589522. doi:10.1007/s15010-010-0039-7.
   PubMed Web of Science ®Google Scholar
• Chan PK, Ngai KL, Lao TT, Wong MC, Cheung T, Yeung AC, Chan MC, Luk SW. Response to booster doses of hepatitis B vaccine among young adults who had received neonatal vaccination. PLoS One. 2014;9:e107163. PMID: 25198289. doi:10.1371/journal.pone.0107163.
   PubMed Web of Science ®Google Scholar
• Jing W, Liu J, Liu M. Eliminating mother-to-child transmission of HBV: progress and challenges in China. Front Med. 2020;14:21–29. PMID:31974872. doi:10.1007/s11684-020-0744-2.
   PubMed Web of Science ®Google Scholar
• Zhao T, Mo Z, Ying Z, Huang T, Che Y, Li G, Yang X, Sun M, Jiang L, Shi L, et al. Post hoc analysis of two clinical trials to compare the immunogenicity and safety of different polio immunization schedules in Chinese infants. Ann Transl Med. 2021;9:253. PMID: 33708880. doi10.21037/atm-20-2537.
   PubMed Web of Science ®Google Scholar